Zepbound

obesity pill
Biotech

Kailera, Hengrui to advance oral obesity drug into 2 new trials

Kailera and its China partner Hengrui have released promising top-line results from a phase 2 trial of their oral version of obesity drug ribupatide.
Kevin Dunleavy Feb 10, 2026 9:25am
Yellow tape measure with a variety of weight loss medication on blue background

Lilly's obesity pill maintains weight lost on injectable GLP-1s

Dec 18, 2025 8:20am
Yellow tape measure with a variety of weight loss medication on blue background

Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial

Aug 7, 2025 6:30am
obesity overweight weight loss weigh

Scholar Rock's SMA drug helps Zepbound patients retain muscle

Jun 18, 2025 9:10am
weight loss scale weigh measure tape obesity overweight

Lilly's amylin data impress with 11% weight loss, tolerability

Jun 16, 2025 4:55am
Ozempic syringe pen and measuring tape on blue background

Novo plots ph. 3 trials for next-gen obesity asset amycretin

Jun 13, 2025 10:35am